Ikarian Capital, LLC Incyte Corp Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $2.07 Million - $2.42 Million	-32,666 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $265,546 - $324,905	-3,867 Reduced 10.58%	32,666 $2.25 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $1.08 Million - $1.18 Million	13,521 Added 58.76%	36,533 $3.07 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $1.47 Million - $1.94 Million	19,312 Added 521.95%	23,012 $1.87 Million
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $274,466 - $403,041	3,700 New	3,700 $385,000

641

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.9B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.